The DOI matches its Crossref record; 81 of the 81 references it cites were found in a registry or an index; 46 of the 79 sources its claims cite were checked for support.
Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1
Open accessAbstract
Ample evidence indicates that the gut microbiome is a tumor-extrinsic factor associated with antitumor response to anti-programmed cell death protein-1 (PD-1) therapy, but inconsistencies exist between published microbial signatures associated with clinical outcomes. To resolve this, we evaluated a new melanoma cohort, along with four published datasets. Time-to-event analysis showed that baseline microbiota composition was optimally associated with clinical outcome at approximately 1 year after initiation of treatment. Meta-analysis and other bioinformatic analyses of the combined data show that bacteria associated with favorable response are confined within the Actinobacteria phylum and the Lachnospiraceae/Ruminococcaceae families of Firmicutes. Conversely, Gram-negative bacteria were associated with an inflammatory host intestinal gene signature, increased blood neutrophil-to-lymphocyte ratio, and unfavorable outcome. Two microbial signatures, enriched for Lachnospiraceae spp. and Streptococcaceae spp., were associated with favorable and unfavorable clinical response, respectively, and with distinct immune-related adverse effects. Despite between-cohort heterogeneity, optimized all-minus-one supervised learning algorithms trained on batch-corrected microbiome data consistently predicted outcomes to programmed cell death protein-1 therapy in all cohorts. Gut microbial communities (microbiotypes) with nonuniform geographical distribution were associated with favorable and unfavorable outcomes, contributing to discrepancies between cohorts. Our findings shed new light on the complex interaction between the gut microbiome and response to cancer immunotherapy, providing a roadmap for future studies.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
16 Valid · 3 Not valid · 12 Not checked · 109 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“Three meta-analyses including multiple tumors and treatments and applying uniform computational approaches have not explained discrepancies among published cohorts14–16.”
§ Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1 > Abstract
What the sources say
- Partly supportedcites [14] Gharaibeh, R. Z. & Jobin, C. Microbiota and cancer immunotherapy: in search of microbial signals. Gut 68, 385–388 (2019). sourceExperimental — accuracy not yet measured
Our copy supports the core point: the authors reanalysed the sequencing data of three published cohorts (Gopalakrishnan, Matson, Routy) through a common pipeline (QIIME/MetaPhlAn2/LEfSe, plus MetAML machine-learning meta-analysis) and conclude that 'analytical pipelines are not responsible for the observed taxa disparity in PD-1 response between the three studies' and that 'processing all data through the same pipeline confirmed the existence of a unique microbial 16S rDNA signal associated with each study'. However, the source is a single reanalysis of three cohort studies, not 'three meta-analyses', and its scope is restricted to anti-PD-1/PD-L1 blockade in metastatic melanoma and non-small cell lung cancer (renal cell carcinoma data were explicitly excluded), not 'various tumors and treatments'. That characterisation is therefore not supported by this paper. (LLM, conf=0.75)
- Partly supportedcites [15] Limeta, A., Ji, B., Levin, M., Gatto, F. & Nielsen, J. Meta-analysis of the gut microbiota in predicting response to cancer immunotherapy in metastatic melanoma. JCI Insight 5, e140940 (2020). sourceExperimental — accuracy not yet measured
Our copy confirms this source is a meta-analysis that uniformly reprocessed multiple cohorts across several treatments: Results (Compositional differences) states 'All the raw sequencing data and metadata for each study were consistently reprocessed and reanalyzed according to a self-developed bioinformatics pipeline', and the Introduction covers anti–PD-1, –PD-L1, –CTLA-4 or combination immunotherapy. However, the 'multiple tumors' qualifier is not supported for this paper: Methods/Results (Study selection and characteristics; Literature review) record that the RCC/NSCLC Routy data set was discarded and the final analysis used exclusively MM patients (66 responders, 64 nonresponders), with the RF classifier trained only on melanoma data. Nor does the paper conclude that discrepancies went unexplained — Results (Compositional differences) reports replicating 'the majority of the findings in each individual study' and Results (Translating microbiome signatures) reports a cross-study signature validated in an independent cohort, even while acknowledging 'substantial heterogeneity across the studies' and no global separation between responders and nonresponders. (LLM, conf=0.72)
- Disputedcites [16] Shaikh, F. Y. et al. A uniform computational approach improved on existing pipelines to reveal microbiome biomarkers of non-response to immune checkpoint inhibitors. Clin. Cancer Res. 27, 2571–2583 (2021). sourceExperimental — accuracy not yet measured
Our copy confirms the descriptive half of the attribution — Shaikh et al. re-analysed five published cohorts (melanoma, NSCLC, RCC, plus HCC/NSCLC validation cohorts) across multiple checkpoint inhibitors using a uniform computational approach and random-effects meta-analysis (Abstract 'Experimental Design'; Introduction; Results 'Evaluation of the Integrated Microbiome Prediction Index in Independent Validation Cohorts'). But it contradicts the claim that this work 'has not explained discrepancies among published cohorts': the Introduction states the reasons for divergent published conclusions (small sample sizes, variable clinical annotation of response, different bioinformatics methods, absence of multiple-hypothesis-testing correction in Results 'Initial analysis of reported bacterial signatures') and the heterogeneity analysis in Results 'Consistent computational analysis across cohorts identifies novel bacterial signatures' reports that all identified R and NR signatures except F. prausnitzii and B. fragilis showed I2=0% across studies, with non-significant moderate heterogeneity for those two. The Discussion summary states the consistent methodology 'improved on existing pipelines' and revealed signatures 'not detected in smaller cohorts'. Residual caveats there (variable R/NR criteria, antibiotic data, regional baseline microbiota, primer/protocol differences) concern remaining limitations and the need for larger prospective validation, not an unexplained discrepancy between cohorts. (LLM, conf=0.68)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Administration of certain gut commensals promotes efficacy of anti-programmed cell death protein-1 (PD-1) therapy in mice, providing evidence that microbiota can drive immunotherapy outcomes4–6.”
§ Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1 > Abstract
What the sources say
- Partly supportedcites [4] Gopalakrishnan, V. et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 359, 97–103 (2018). sourceExperimental — accuracy not yet measured
In the mouse FMT experiments (Fig. 4G–I; page not specified), stool from patients who responded to anti-PD-1 treatment reduced tumor growth and improved mice’s responses to anti-PD-L1 therapy. This supports the broader point that gut microbiota can affect immunotherapy outcomes in mice, but the paper reports fecal transplants rather than administration of specific commensals, and the mouse treatment was anti-PD-L1, not anti-PD-1. (LLM, conf=0.89)
- Partly supportedcites [5] Matson, V. et al. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science 359, 104–108 (2018). sourceExperimental — accuracy not yet measured
The mouse experiments described in our copy (section labeled Abstract; page unavailable) found that fecal microbiota from responding patients made anti–PD-L1 treatment markedly effective, whereas microbiota from nonresponders did not. This supports an effect of administered gut microbiota on immunotherapy outcomes in mice, but the mice received fecal material rather than specific isolated commensals, and the treatment tested was anti–PD-L1, not anti–PD-1. (LLM, conf=0.88)
- Not checked yetcites [6] Routy, B. et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 359, 91–97 (2018). source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Additionally, there is evidence that the microbiome is associated with development of immune-related adverse events (irAEs) following ICB7–9.”
§ Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1 > Abstract
What the sources say
- Not checked yetcites [7] Chaput, N. et al. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann. Oncol. 28, 1368–1379 (2017). source
- Supportedcites [8] Dubin, K. et al. Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis. Nat. Commun. 7, 10391 (2016). source
The Abstract (p. 1) states that checkpoint blockade with ipilimumab (CTLA-4) 'is associated with new-onset, immune-mediated colitis' and that pre-inflammation faecal microbiota composition correlates with subsequent colitis development — Bacteroidetes abundance and polyamine-transport/B-vitamin-biosynthesis pathways being associated with resistance versus risk. The Results ('Members of Bacteroidetes phylum associated with resistance', p. ~5) and the Discussion (p. ~7) reinforce this association with an adverse inflammatory event of checkpoint-blockade therapy, and the Discussion extends the possibility to other immunotherapies. Thus our copy supplies direct evidence for the cited claim that the microbiome is associated with an immune-related adverse event following ICB (colitis after CTLA-4 blockade in metastatic melanoma). (LLM, conf=0.82)
- Not checked yetcites [9] Andrews, M. C. et al. Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. Nat. Med. 27, 1432–1441 (2021).
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Consistent with published studies in multiple settings21–24, PD-1-treated patients with melanoma with a high NLR had poorer survival (OS/PFS) than those with a low NLR.”
§ Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1 > Results > Systemic and gut inflammation associates with poor response.
What the sources say
- Supportedcites [21] Capone, M. et al. Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab. J. Immunother. Cancer 6, 74 (2018). source
The Results (NLR and dNLR, PFS and OS) report shorter progression-free and overall survival for nivolumab-treated melanoma patients with baseline NLR ≥5 than for those with NLR <5. The Background identifies nivolumab as a PD-1-targeting therapy. (LLM, conf=0.94)
- Partly supportedcites [22] Valero, C. et al. Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors. Nat. Commun. 12, 729 (2021). sourceExperimental — accuracy not yet measured
The Results sections “Pan-cancer analysis of NLR” and “Outcomes stratified by cancer type” report poorer OS and PFS with high NLR among immune-checkpoint-inhibitor-treated patients, including analyses by cancer type. The passages do not establish the stated comparison specifically for melanoma patients receiving PD-1 therapy; they report it for the broader ICI-treated cohort and cancer-type subgroups. (LLM, conf=0.85)
- Partly supportedcites [23] Ascierto, P. A. et al. Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations. J. Immunother. Cancer 7, 91 (2019). sourceExperimental — accuracy not yet measured
The Discussion reports that high NLR has been associated with poor outcomes in melanoma, including in patients treated with immunotherapy. But this study found that the NLR relationship differed by BDX008 classification: PFS and OS were similar for high- and low-NLR patients classified as BDX008−. The Results also report no significant overall NLR effect in the interaction model, so the unqualified comparison overstates this paper’s findings. (LLM, conf=0.88)
- Supportedcites [24] Yang, A. P., Liu, J. P., Tao, W. Q. & Li, H. M. The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients. Int. Immunopharmacol. 84, 106504 (2020). source
The citation supports the background reference to published studies in other settings, not the citing authors’ own finding about PD-1-treated melanoma patients. This paper’s Discussion reports elevated NLR as a prognostic biomarker in COVID-19 patients, making it an example of such a study; it does not report melanoma OS or PFS. (LLM, conf=0.88)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“As in previous reports29–31, landmark analysis (landmark time point for OS set at 10 months after therapy initiation) identified that any-grade irAEs were associated with improved PFS (Supplementary Table 6 and Supplementary Fig. 4a).”
§ Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1 > Results > Gut microbial signatures are associated with distinct immune-related adverse events.
What the sources say
- Not checked yetcites [29] Das, S. et al. Immune-related adverse events and immune checkpoint inhibitor efficacy in patients with gastrointestinal cancer with food and drug administration-approved indications for immunotherapy. Oncologist 25, 669–679 (2020). source
- Supportedcites [30] Matsuoka, H. et al. Correlation between immune-related adverse events and prognosis in patients with various cancers treated with anti PD-1 antibody. BMC Cancer 20, 656 (2020). source
The Results section 'Therapeutic effects according to the onset of irAEs' states the median PFS was significantly longer in the irAE group (17.6 months) than in the non-irAE group (3.0 months, p < 0.01), and the Abstract reports both median OS and PFS significantly longer in patients with irAEs. The paper's irAE group is defined irrespective of severity (115 patients, 41.1%, with grade 3-4 in only 8), so it corresponds to 'any-grade' irAEs. The landmark-analysis design and 10-month OS landmark are the citing authors' own method, not attributed to this source; the cited finding of an any-grade irAE/PFS association is what this paper reports. (LLM, conf=0.88)
- Not checked yetcites [31] Suo, A. et al. Anti-PD-1-induced immune-related adverse events and survival outcomes in advanced melanoma. Oncologist 25, 438–446 (2020). source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
90 more claims · 11 with their cited sources checked
Create a free account to see all 140 claims and to verify the 33 references still open.
- Probably not a substantial claim. 11
- It may state two separate claims as one. 37
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In multiple cancer types, gut microbiota composition has been associated with response and adverse effects of immune checkpoint inhibitors (ICIs) [2, 3, 4].”
From Gut microbiota diversity is prognostic and associated with benefit from chemo-immunotherapy in metastatic triple-negative breast cancer (2025) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although not yet used clinically, stool miRNA panels are a novel dimension of the “exfoliome” of the gut epithelium that could furnish indirect readouts of microbiome status in disease.24,132”
From Gut dysbiosis in oncology: a risk factor for immunoresistance (2026) · doi:10.1038/s41422-025-01212-6 · cites this paper as [132]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Over the past decade, following the epidemiological demonstration of the negative effect of antibiotics on the efficacy of ICIs13,42,90, specific microbial taxa have been associated with response or resistance to ICIs across distinct cancer types26,38–40,42,91–100.”
From Gut OncoMicrobiome Signatures (GOMS) as next-generation biomarkers for cancer immunotherapy (2023) · cites this paper as [40]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, in several cohorts of patients with melanoma, the clinical response to anti-PD-1 antibodies correlated with the expression of the CUTC gene170 in the faecal microbiome40,91,128.”
From Gut OncoMicrobiome Signatures (GOMS) as next-generation biomarkers for cancer immunotherapy (2023) · cites this paper as [40]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Our meta-analysis of microbial sequencing data from nine independent αPD-1-treated melanoma cohorts82–88 revealed a higher abundance of pfl, a key enzyme in bacterial formate production, linked to ICI efficacy.”
From Exercise-induced microbiota metabolite enhances CD8 T cell antitumor immunity promoting immunotherapy efficacy (2025) · cites this paper as [86]
Experimental — accuracy not yet measured
28 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1 > Methods > Reference-independent binning analysis of metagenomic data.
“Reads for all samples from all five cohorts were combined into one large file and larger sequence contigs were assembled using MEGAHIT (1.2.9)70,71. Reads longer than 1,000 bp were used in the analysis.”
§ Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1 > Methods > DNA/RNA extraction, sequencing and analysis.
“The DNA library was prepared using the Nextera DNA Flex Library Prep Kit, quantified using Qubit, and sequenced on the NovaSeq System (Illumina) using the 2 × 150 base-pair (bp) paired-end protocol.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1 > Methods > Meta-analysis methodologies.
“Taxa that agreed in directionality of NP versus P differences in more than four of five datasets were considered.”
§ Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1 > Methods > Meta-analysis methodologies.
“When taxa in one of five datasets failed to agree in directionality, its P values were assigned as 0.999 and ratio as one.”
Citations
Cites
Trimmomatic: a flexible trimmer for Illumina sequence data
Bolger, A. M., Lohse, M., & Usadel, B. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu170 · Cited by 65,548
Fast gapped-read alignment with Bowtie 2
Langmead, B., & Salzberg, S. L. (2012) · Nature Methods · doi:10.1038/nmeth.1923 · Cited by 56,400
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Cytoscape: A software Environment for integrated models of biomolecular interaction networks
Shannon, P., Markiel, A., Ozier, O., Baliga, N. S., Wang, J. T., Ramage, D., Amin, N., Schwikowski, B., & Ideker, T. (2003) · Genome Research · doi:10.1101/gr.1239303 · Cited by 51,888
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Prokka: rapid prokaryotic genome annotation
Seemann, T. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu153 · Cited by 18,818
McCullagh, P., & Nelder, J. A. (1989) · doi:10.1007/978-1-4899-3242-6 · Cited by 16,836
Metagenomic biomarker discovery and explanation
Segata, N., Izard, J., Waldron, L., Gevers, D., Miropolsky, L., Garrett, W. S., & Huttenhower, C. (2011) · Genome Biology · doi:10.1186/gb-2011-12-6-r60 · Cited by 16,192
A training algorithm for optimal margin classifiers
Boser, B. E., Guyon, I. M., & Vapnik, V. N. (1992) · Proceedings of the fifth annual workshop on Computational learning theory · doi:10.1145/130385.130401 · Cited by 11,992
Structure, function and diversity of the healthy human microbiome
The Human Microbiome Project Consortium (2012) · Nature · doi:10.1038/nature11234 · Cited by 11,726
Cited by
Hallmarks of aging: An expanding universe
López-Otín, C., Blasco, M. A., Partridge, L., Serrano, M., & Kroemer, G. (2023) · Cell · doi:10.1016/j.cell.2022.11.001 · Cited by 6,549
Bender, M. J., McPherson, A. C., Phelps, C. M., Pandey, S. P., Laughlin, C. R., Shapira, J. H., Medina Sanchez, L., Rana, M., Richie, T. G., Mims, T. S., et al. (2023) · Cell · doi:10.1016/j.cell.2023.03.011 · Cited by 732
Self-citationEmbracing cancer complexity: Hallmarks of systemic disease
Swanton, C., Bernard, E., Abbosh, C., André, F., Auwerx, J., Balmain, A., Bar-Sagi, D., Bernards, R., Bullman, S., DeGregori, J., et al. (2024) · Cell · doi:10.1016/j.cell.2024.02.009 · Cited by 540
Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial
Routy, B., Lenehan, J. G., Miller, W. H., Jamal, R., Messaoudene, M., Daisley, B. A., Hes, C., Al, K. F., Martinez-Gili, L., Punčochář, M., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02453-x · Cited by 526
Self-citationGut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies
(2022) · doi:10.1186/s13045-022-01273-9 · Cited by 495
Metadata
- Authors
- McCulloch, J. A., Davar, D., Rodrigues, R. R., Badger, J. H., Fang, J. R., Cole, A. M., Balaji, A. K., Vetizou, M., Prescott, S. M., Fernandes, M. R., Costa, R. G. F., Yuan, W., Salcedo, R., Bahadiroglu, E., Roy, S., DeBlasio, R. N., Morrison, R. M., Chauvin, J.-M., Ding, Q., Zidi, B., Lowin, A., Chakka, S., Gao, W., Pagliano, O., Ernst, S. J., Rose, A., Newman, N. K., Morgun, A., Zarour, H. M., Trinchieri, G., & Dzutsev, A. K.
- Affiliations
- National Cancer Institute (US)
- University of Pittsburgh (US)
- Frederick National Laboratory for Cancer Research (US)
- Oregon State University (US)
- Corresponding author
- Zarour, Hassane M.
- Trinchieri, Giorgio
- Dzutsev, Amiran K.
- ORCID
- McCulloch, John A.
- Davar, Diwakar
- Rodrigues, Richard R.
- Badger, Jonathan H.
- Fang, Jennifer R.
- Cole, Alicia M.
- Balaji, Ascharya K.
- Prescott, Stephanie M.
- Fernandes, Miriam R.
- Costa, Raquel G. F.
- Yuan, Wuxing
- Bahadiroglu, Erol
- Roy, Soumen
- Morrison, Robert M.
- Zidi, Bochra
- Lowin, Ava
- Chakka, Saranya
- Gao, Wentao
- Pagliano, Ornella
- Newman, Nolan K.
- Morgun, Andrey
- Zarour, Hassane M.
- Trinchieri, Giorgio
- Dzutsev, Amiran K.
- Venue
- Nature Medicine
- Published
- 2022-02-28
- Volume
- 28
- Issue
- 3
- Pages
- 545-556
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- PMC
- PMC10246505
- OpenAlex
- W4214737502
- Cited by
- 472
- References
- 81
- Citations by year
- 2026: 102 · 2025: 119 · 2024: 104 · 2023: 97 · 2022: 49
- FWCI
- 39.03
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Melanoma Research Foundation (Melanoma Breakthrough Foundation Breakthrough Consortium 2020)
- U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01 CA257265, P50 CA254865, R01 CA228181, R01 CA222203, P50 CA254865))
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Dentistry › Periodontics › Oral microbiology and periodontitis research
- Keywords
- gut microbiota, melanoma, anti-PD-1 therapy, immune checkpoint inhibitors, cancer immunotherapy response, immune-related adverse events, Lachnospiraceae, Ruminococcaceae, Streptococcaceae, actinobacteria, Gram-negative bacteria, neutrophil-to-lymphocyte ratio, microbial signatures, outcome prediction
- MeSH terms
- Gastrointestinal Microbiome, Bacteria, Humans, Immunotherapy, Melanoma, Microbiota
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1. https://app.cochat.ai/papers/10.1038/s41591-022-01698-2
- The paper
- McCulloch, J. A., Davar, D., Rodrigues, R. R., Badger, J. H., Fang, J. R., Cole, A. M., Balaji, A. K., Vetizou, M., Prescott, S. M., Fernandes, M. R., Costa, R. G. F., Yuan, W., Salcedo, R., Bahadiroglu, E., Roy, S., DeBlasio, R. N., Morrison, R. M., Chauvin, J.-M., Ding, Q., . . . Dzutsev, A. K. (2022). Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1. Nature Medicine. https://doi.org/10.1038/s41591-022-01698-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.